Administered as an intravenous infusion by a healthcare professional. Must not be administered as an intravenous push or bolus. The first dose should be infused over 90 minutes; subsequent doses can be infused over 30 minutes if the first infusion was well tolerated.

Trastuzumab binds specifically to the extracellular domain of the human epidermal growth factor receptor 2 (HER2) protein, preventing its dimerization and downstream signaling, which inhibits the proliferation of HER2-overexpressing tumor cells.

• •Known hypersensitivity to Trastuzumab or any component of the formulation.
• •Severe dyspnea at rest due to complications of advanced malignancy or pre-existing pulmonary disease.

Store vials in a refrigerator at 2°C to 8°C. Do not freeze. Protect from light. Reconstituted solution should also be stored at 2°C to 8°C and used within 28 days.

No specific antidote. Management involves supportive care and close monitoring of cardiac and pulmonary function.

Pregnancy Category D. Can cause fetal harm. Avoid use during pregnancy. Advise women of reproductive potential to use effective contraception. It is unknown whether Trastuzumab is excreted in human milk; due to the potential for serious adverse reactions in breastfed infants, advise lactating women not to breastfeed during treatment and for 7 months following the last dose.